XORTX Therapeutics IncTSXV:XRTXView on NASDAQ
- LAST PRICE1.7300
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.7300/ 800
- Ask / Lots2.1000/ 100
- Open / Previous Close--- / 1.7300
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | XRTX |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
XORTX Therapeutics Inc | 5.0M | -34.3x | --- |
Marvel Biosciences Corp | 7.4M | -3.1x | --- |
Glow Lifetech Corp | 6.7M | -1.6x | --- |
Telo Genomics Corp | 8.2M | -2.9x | --- |
Quest Pharmatech Inc | 5.9M | 0.4x | --- |
GeneTether Therapeutics Inc | 3.9M | -4.7x | --- |
Company Information
XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The Company has three product development programs: XRx-008, which is a program for the treatment of ADPKD; XRx-101, which is a program to treat acute kidney injury (AKI) associated with respiratory virus infection, AKI and associated health consequences, and XRx- 225, a program for the treatment of T2DN. The Company's XRx-008 program is designed for longer term stable chronic oral dosing of xanthine oxidase inhibitors.
Contact Information
- Headquarters
- 3710 - 33rd Street NWCALGARY, AB, Canada T2L 2M1
- Phone
- 403-455-7727
- Fax
- 403-607-2621
Executives
- Independent Non-Executive Chairman of the Board
- Anthony Giovinazzo
- President, Chief Executive Officer, Director
- Allen Davidoff
- Interim Chief Financial Officer
- James Fairbairn
- Chief Business Officer
- Stacy Evans
- Chief Medical Officer
- Stephen Haworth
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.0M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 2.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.22 |
EPS | $-0.05 |
Book Value | $3.25 |
P/E Ratio | -34.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
